Stockscreener 앱 받기
1.95
1.56%
0.03
시장 영업 전:
1.86
-0.09
-4.62%
전일 마감가:
$1.92
열려 있는:
$1.99
하루 거래량:
218.76K
Relative Volume:
3.82
시가총액:
$3.54M
수익:
-
순이익/손실:
$-2.77M
주가수익비율:
-0.7369
EPS:
-2.6464
순현금흐름:
$-2.69M
1주 성능:
-5.80%
1개월 성능:
-4.41%
6개월 성능:
-1.27%
1년 성능:
-53.06%
1일 변동 폭
$1.85
$2.09
1주일 범위
$1.5901
$2.65
52주 변동 폭
$1.5901
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
1.95 | 4.23M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xortx Therapeutics Inc 주식(XRTX)의 최신 뉴스
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - kalkine.ca
XORTX Therapeutics Shares Rise 16.11% After HoursXORTX Therapeutics (NASDAQ:XRTX) - Benzinga
XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media
Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks
XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - The Manila Times
XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan
Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - kalkinemedia.com
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Announces Termination and Postponement of Investor Relations Program - marketscreener.com
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn
XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionModified Schiff - vinanet.vn
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XRTX Q1 2024 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage InvestmentSubscription Growth Report - vinanet.vn
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Announces Director Resignation - The Manila Times
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan
XRTX Q1 2024 Earnings: Larger-Than-Expected Loss Highlights Developmental Stage ChallengesProfitability Analysis - vinanet.vn
Xortx Therapeutics Inc (XRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
1.96%
자본화:
|
볼륨(24시간):